Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q4 FY20 results · Jan–Mar 2020
Ajanta Pharma reported revenue from operations of ₹681.96 crore (up 32.4% from Q4 FY19) and net profit of ₹129.16 crore (up 45.3% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 681.96 | 515.16 | +32.4% | 651.21 | +4.7% |
| Other income | 56.69 | 1.63 | 35x | 14.64 | +287.2% |
| Total income | 738.65 | 516.79 | +42.9% | 665.85 | +10.9% |
| Profit before tax | 175.86 | 109.19 | +61.1% | 175.10 | +0.4% |
| Net profit for the period | 129.16 | 88.89 | +45.3% | 107.55 | +20.1% |
| EPS, basic (₹) | 14.80 | 10.10 | +46.5% | 12.33 | +20.0% |
| Net margin (%) | 18.9 | 17.3 | 16.5 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 560.68 | 413.53 | +35.6% | 530.55 | +5.7% |
| Other income | 54.10 | 3.19 | 17x | 51.17 | +5.7% |
| Total income | 614.78 | 416.72 | +47.5% | 581.72 | +5.7% |
| Profit before tax | 129.62 | 52.01 | +149.2% | 165.77 | −21.8% |
| Net profit for the period | 88.51 | 41.37 | +113.9% | 108.32 | −18.3% |
| EPS, basic (₹) | 10.14 | 4.70 | +115.7% | 12.41 | −18.3% |
| Net margin (%) | 15.8 | 10.0 | 20.4 |
Consolidated
- Filed with BSE
- 21 May 2020, 13:30 IST
- Board meeting
- 20 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 21 May 2020, 13:30 IST
- Board meeting
- 20 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE